enGene Therapeutics ENGN
NASDAQ ENGN
$2.00 +0.05 (+2.56%)
At close: Sep 30, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Other financing activities (2024 - 2026)

Updated

enGene Therapeutics (ENGN) reported Other financing activities of -$70,000 for fiscal Q2 2026 (quarter ended Apr 30, 2026).

Analysis

enGene Therapeutics (ENGN) Other financing activities (2024 - 2026) Analysis & Trends

For FY2024 (ended Oct 31, 2024), enGene Therapeutics posted Other financing activities of $585,000.

  • By fiscal year, Other financing activities came in at $391,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 enGene Therapeutics 134.03 Mn 134.03 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 -70,000.00
Jan 31, 2026 615,000.00
Apr 30, 2024 143,000.00
Jan 31, 2024 442,000.00
API Access

enGene Therapeutics Other financing activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-financing-activities&ticker=ENGN&period=max&api_key=YOUR_API_KEY